

Index

A

- AA-[α -³²P]GTP, 332, 335, 337
- AC, *see* Adenylyl cyclase
- Acylation, 400
- Addiction, *see* Drug addiction
- Adenosine
 - actions of, 327
 - G protein downregulation and, 193
 - in radioligand studies, 335
- Adenosine deaminase, 335
- Adenosine receptors
 - caffeine and, 327, 329
 - G protein activity and, 336–342
 - ischemia and, 328–331, 342, 343
 - neuroleptics and, 342–344
 - neuropsychiatric disorders and, 342–344
 - physiological functions, 328–330
 - radioligand binding studies, 333–336
 - signal transduction and, 330–332
 - subtypes, 327, 328
- Adenosine-A1 receptors, 193
 - actions of, 328, 329
 - adenylyl cyclase and, 330–332
 - G proteins and, 331, 332
 - ion channels and, 331
- Adenosine-A2 receptors
 - in Alzheimer's disease, 343
 - dopamine-D2 receptors and, 329, 330
 - G proteins and, 332
 - types, 329
- Adenosine-A3 receptors, 330, 332
- Adenylyl cyclase (AC), 3, 96, 98, 122, 354
 - adenosine receptors and, 330–332
 - in affective disorders, 56
 - in age-related disease, 57
 - in Alzheimer's disease, 343
 - antidepressants and, 67, 68, 294, 295, 362, 363
 - ATP and, 237
 - cAMP production and, 237
 - in circadian rhythm, 251, 252
 - denervation and, 155
 - electroconvulsive shock and, 362, 363
 - G proteins and, 143, 144, 155, 191, 236, 395, 396
 - 5-HT receptors and, 66
 - inhibition of, 166, 167
 - isoforms, 144
 - lithium and, 299–302, 357, 358, 359
 - melatonin modulation of, 237–241
 - in mood disorders, 288, 289
 - morphine regulation of, 209–211
 - in neuropsychiatric disorders, 63
 - opioid receptors and, 212
 - in posttraumatic stress disorder, 293
 - in receptor gene expression, 257, 258
 - in schizophrenia, 54, 55, 402, 413
- AD FX-116, 359
- Adipocytes, 68, 70, 193
- ADP ribosylation, *see also* Cholera toxin, Pertussis toxin
 - of G proteins, 3, 95, 165, 193, 241, 355

ADP ribosylation assay, 380–389
ADP ribosylation factor (ARF), 30
Adrenalectomy, 308
 β -Adrenergic receptors
 in affective disorders, 55, 56
 antidepressants and, 294, 296–298, 361
 in bipolar disorder, 364, 365
 desensitization, 139
 dissociation constants, 297, 301
 electroconvulsive shock and, 361
 lithium and, 300–302, 357–359
 in major depression, 367
 in mitral valve prolapse, 293
 in mood disorders, 288, 289
 in panic disorder, 292
 thyroid hormone and, 308
 valproic acid and, 305–307
 β 2-Adrenergic receptors
 protein kinase desensitization, 169
 regulation of transcription in, 257, 258
Affective disorders, 55–57, 66, *see also* specific types
Affinity chromatography, in
 opioid receptor purification, 213, 214
Age-related diseases, 57–59
Agonist(s)
 in homologous desensitization, 179
 neurotransmitter receptors and, 2
 [³⁵S]GTP γ S assay and, 16, 20–22
Akinesia, 148
Albright's Hereditary
 Osteodystrophy, 53, 284, 285, 400, 401
Alcoholism, 60–62
 α -Adrenergic receptors, 58, 166, 241, 403, 406
Aluminum intoxication, 62, 63
Alzheimer's disease, 57–59, 84, 122, 343, 402
 γ -Aminobutyric acid, *see* GABA
 γ -Aminobutyric acid receptors, *see* GABA receptors
Amitriptyline, 361, 363
Amphetamine, 361

Amygdala, 382, 384, 385
Antibodies
 in G protein labeling, 127
 in small-mol-wt G protein labeling, 36, 37
Antidepressants, 55, 131
 adenylyl cyclase and, 67, 68, 294, 295, 362, 363
 atypical, 294
 gene expression and, 313
 G proteins and, 293–299, 361–363, 369
 signal transduction pathways and, 283, 284
 tricyclic, 294, 296, 361
Antipsychotic drugs, *see* Neuroleptics
Anxiety disorders, 66
 etiology, 283–287
 hormones and, 307–310
 second messengers in, 292, 293
 signal transduction in, 312, 313
AP-1 transcription factor, 258, 259
Arachidonic acid, 92, 407
ARF, *see* ADP ribosylation factor
Arteries, melatonin receptors in, 227, 228
ATP, adenylyl cyclase and, 237
Autoradiography
 emulsion, 23
 neurotransmitter receptors and, 2–4
 in vitro, *see* [³⁵S]GTP γ S assay

B

Baclofen, 15
Bacterial toxin, *see* Cholera toxin, Pertussis toxin
Basal binding, in [³⁵S]GTP γ S assay, 8–11
Basal ganglia
 function, 144–146
 G proteins in, 143–147
 in Parkinson's disease, 148, 149
 structure, 143, 144
BD, *see* Bipolar disorder
Behavioral sensitization, 310–312
Benzodiazepine, 342
Benzodiazepine receptors,
 melatonin and, 225, 226

- Bipolar disorder (BD), 289–291,
310, 353, 402
G proteins and, 365–367
lithium and, 299, 359
mononuclear leukocytes and,
290, 364–366
signal transduction pathways
and, 364, 365
treatment development, 312
Blood vessels, melatonin receptors
in, 227, 228
Bradykinesia, 148
Brain
abnormalities in schizophrenia,
379, 408
adenosine receptors in, 328–330
drug addiction and, 189, 190
effects of neuroleptics on, 125–
135
electrophysiology in, 252–254
G protein abundance in, 18
GTPase-activating protein in,
40, 41
melatonin binding sites in, 226–
228
PKC-induced receptor
uncoupling in, 180
small-mol-wt G proteins in, 35–
37
tissue preparation for
[³⁵S]GTPγS assay, 11, 13,
14
Brain paste standard assay, 12, 13
Breast cancer, melatonin levels in,
225
Buprenorphine, 21, 22
Buspirone, 66
C
Caffeine, adenosine receptors and,
327, 329
Calcium
adenosine-A1 receptors and, 331
in aluminum intoxication, 62, 63
dopamine release and, 256, 257
functions, 246, 247
IP₃ and, 244, 396, 397
melatonin and, 247, 248, 255–257
mobilization by G protein-
coupled receptors, 167, 168
PKC and, 163, 171–173
regulation, 246–248
TPA inhibition of, 171–175
Calcium channels, 165–167, 246,
247, 397
Calmodulin, 250, 262
cAMP, *see* Cyclic AMP
cAMP-dependent protein kinase A
(PKA), 122, 191, 237
in affective disorders, 55, 56
CREB downregulation and, 201,
202
in Parkinson's disease, 57
in receptor desensitization, 168,
169
receptor gene expression and,
258
in schizophrenia, 412
in signal transduction
pathways, 396
cAMP response element binding
protein (CREB), 196–202, 259,
396
cAMP response element (CRE),
259, 396
Cancer
melatonin and, 225, 227
ras p21 protein and, 40, 41
Cannabinoid receptor system, 7,
20, 21
Captopril, 286
Carbamazepine, 342, 343, 357, 360,
361
Caudate head, 65, 382–386, 408
Caudate nucleus, *see* Caudate head
CCPA, 333, 334
Central nervous system (CNS)
aluminum intoxication, 62, 63
G proteins and, 286, 287
lipids in, 59
Cerebral cortex, 60
c-fos gene, 258, 259
C6 glioma cells, 297
cGMP, *see* Cyclic guanosine
monophosphate
CGS 21680, 334, 336
2-Chloroadenosine, 340
6-Chloromelatonin, 245
Cholera toxin (CTX), ADP
ribosylation, 95, 355
in age-related disease, 57

in alcoholism, 61, 62
valproic acid and, 306, 307
Cholesterol, 31, 59
Chromatography
affinity, in opioid receptor
purification, 213, 214
thin-layer, 39, 40
Circadian rhythm
melatonin and, 223, 224, 250–
252
regulation of gene expression
in, 258, 259
CIA, *see* 2-Chloroadenosine
Clomipramine, 64, 362, 363
Clorgyline, 362
Clozapine, 123, 125–135
CNS, *see* Central nervous system
Cocaine, 311, 361, 403, 411
Congestive heart failure, 286
Corticosterone, 260, 308
Cortisol, 260
Coupling efficiency, [³⁵S]GTPγS
assay and, 18, 20, 21
CRE, *see* cAMP response element
CREB, *see* cAMP response element
binding protein
CTP, 213
Cushing's syndrome, 260
Cyclic AMP (cAMP), 122, 191
adenylyl cyclase and, 237
in affective disorders, 56
in alcoholism, 61, 62
in aluminum intoxication, 62, 63
analogs, 251
in bipolar disorder, 364, 365
chronic morphine and, 191–193
in circadian rhythm, 251, 252
in dopamine receptor studies,
97
in drug addiction, 195, 196
hormonal regulation of, 308
inhibition of, 165
isoproterenol stimulated, 289
lithium and, 357, 358
in major depression, 368
melatonin and, 238, 239, 240,
241, 248–250
in mood disorders, 287–289
in 6-OHDA lesion model, 151
in pseudohypoparathy-
roidism, 285

in receptor desensitization, 169
in receptor gene expression,
257, 258
in schizophrenia, 406, 407, 412
in selective uncoupling, 177,
178
in signal transduction
pathways, 396
valproic acid and, 305–307
Cyclic guanosine monophosphate
(cGMP), 250, 252, 259

D

DADLE, 215
DAG, *see* Diacylglycerol
DAMGO, 6, 7, 10, 15, 21, 22, 213,
215
D1.D2 receptor interactions
coexpression studies in, 91, 92
D2 receptor subtypes and, 100,
101
G proteins and, 94–99
ligand binding and, 87–91
in neuropsychiatric disorders,
86, 87
in schizophrenia, 87, 91, 94, 99
synthetic peptide studies, 96–98
unicellular, 92–94
Denervation
adenylyl cyclase and, 155
MPTP lesions, 151–153
6-OHDA lesions, 150, 151
Dependence, in drug addiction,
189
Depression, *see also* Affective
disorders
major, 353, 367, 368
manic, 56, 304
refractory, 310
unipolar, 288, 289
Desensitization
defined, 228, 229
of melatonin receptors, 231
Desipramine, 67, 294, 296, 361–363
Dexamethasone, 310
Diacylglycerol (DAG), 163, 396
activity of, 244
in receptor desensitization, 169,
170
in schizophrenia, 405

- Diazepam, 342
- Dopamine
- calcium-dependent release, 256, 257
 - Parkinson's disease and, 140, 147, 148
 - PLG and, 124
 - prostaglandin E1 receptors and, 406, 407
 - in schizophrenia, 120, 411
 - in striatal signal transduction, 146, 147
- Dopamine neurons
- in behavioral sensitization, 311
 - in drug addiction, 190
- Dopamine receptors, *see also* D1·D2 receptor interactions; Mesolimbic dopamine system
- extrapyramidal side effects and, 123
 - functions, 82, 83
 - genes for, 83, 84
 - in Huntington's disease, 402
 - in MPTP lesion models, 152, 153
 - neuroleptics and, 121–123
 - in neuropsychiatric disorders, 86, 87
 - in 6-OHDA lesion model, 150, 151
 - in Parkinson's disease, 87, 140
 - PLG and, 124
 - in schizophrenia, 54, 55, 65, 84–86, 120, 121, 387, 393, 402, 411, 413
 - supersensitivity, 122, 123, 128–131, 139
 - types, 81, 82, 142
- Dopamine-D1 receptors, 142
- functions, 81, 82
 - genes for, 83, 84
 - G proteins and, 122, 143
 - in L-DOPA-induced dyskinesia, 154
 - in 6-OHDA lesion model, 150, 151
 - striatal localization, 144–146
- Dopamine-D2 receptors, 142
- adenosine-A2 receptors and, 329, 330
 - in behavioral sensitization, 311
 - calcium mobilization and, 167, 168
 - coupling specificity, 166, 167
 - desensitization, 164, 168, 179
 - extrapyramidal side effects and, 123
 - functions, 82
 - genes for, 83
 - G proteins and, 122, 143
 - inhibitory actions of, 164, 165
 - in L-DOPA-induced dyskinesia, 154
 - neuroleptics and, 121–123, 129, 131
 - in 6-OHDA lesion model, 150, 151
 - in PLC stimulation, 165, 166
 - prolactin and, 165
 - pseudosubstrate domains, 175, 176
 - resistance to PKC, 173–175
 - in schizophrenia, 84–86, 120, 121
 - selective uncoupling in, 177
 - striatal localization, 144–146
 - subtypes, 99–101
- Dopaminergic hypothesis, of schizophrenia, 119, 120
- DPCPX, 333, 334
- DPDPE, 213, 217
- Drug addiction
- cellular basis of behavior, 194, 195
 - effects on brain, 189, 190
 - neurons and, 59, 60, 190
 - rat strain differences in, 195, 196
- Drugs, *see also* Neuroleptics; specific types
- psychotropic, 59, 60
 - self-administration paradigm, 194, 195
- DSTBULET, 213
- Dynorphin, 146
- Dyskinesia, 87, 153, 154, *see also* Extrapyramidal side effects
- E**
- ECS, *see* Electroconvulsive shock
- Effector enzymes, *see* specific types
- Electroconvulsive shock (ECS), 68, 298
- adenylyl cyclase and, 362, 363
 - β -adrenergic receptors and, 361

Electrophoresis, *see* SDS-PAGE
Electrophysiology, 252–254
Endocrine activity, 254–257
Endocrine tumors, 53, 54, 284
Endoplasmic reticulum, 397
Entorhinal cortex, 409
Epinephrine, 336
EPS, *see* Extrapyramidal side effects

Epstein-Barr virus, 407
ER, *see* Estrogen receptor
Estradiol, 308
Estrogen receptor (ER), 225
Ethanol, *see* Alcoholism
Exocytosis, small-mol-wt G proteins and, 42, 43
Extrapyramidal side effects (EPS)
 D1.D2 receptor interactions in, 87
 haloperidol and, 132, 133, 135
 neuroleptics and, 123, 124, 128

F

Farnesylation, 31, 400
Fatty acids, 70
Fentanyl, 21, 22
Fischer 344 rat, 195
Flumazenil, 226
Fodrin, 399, 400, 410, 411
Follicular fluid, 224
Forskolin, 54, 68, 231, 406
Fos protein, 258

G

GABA, 225, 226, 252
GABA receptors, 7, 15, 66, 67, 166
GAP, *see* GTPase-activating protein
GDP
 in G protein activation, 234, 235, 356, 394
 in Scatchard assay, 19
 in [³⁵S]GTPγS assay, 8, 9, 10, 14, 15, 338–340
Gene expression
 antidepressants and, 313
 effects of lithium on, 360
 melatonin modulation of, 257–259
Geranylgeranylation, 31, 400

Gi proteins
 adenylyl cyclase and, 144
 in affective disorders, 55–57
Gloma cells, 297
Globus pallidus, 146, 382, 383, 385
Glucocorticoids, 259, 309
Glutamate, 411
GnRH, *see* Gonadotropin-releasing hormone
Gonadal steroids, in signal transduction, 308
Gonadotropin-releasing hormone (GnRH), 247, 248, 255, 256
Gpp(NH)p, 208–211, 289, 290, 406
G protein-coupled receptors, *see also* Neurotransmitter receptors
 activation, 336
 coupling domains, 167
 coupling specificity in, 166, 167
 desensitization, 168–170, 179
 hormones and, 260, 261
 multiple signal pathways in, 164–168, 241
 in PKC stimulation, 165, 166
 pseudosubstrate domains, 173–175, 176
 R7G group, 257
 uncoupling, 170–173, 175–178
G protein receptor kinases (GRKs), 168, 169
G proteins, *see also* Small-mol-wt G proteins
 activation, 3, 4, 190, 191, 234, 235, 356, 394
 ADP ribosylation, 3, 95, 165, 193, 241, 355, *see also* Cholera toxin; Pertussis toxin
 antisense oligonucleotide “knockdown,” 155
 desensitization, 193, 194
 effector enzymes and, 395–397
 in eukaryotes, 29
 fodrin and, 399, 400
 forms and categories, 3, 29, 30, 143, 190, 233, 234, 354, 398
 GTP and, 2, 3, 5, 191, 234, 235, 356, 394
 heterotrimeric, 3, 29
 i2 loop phosphorylation, 178, 179

mutations in, 284, 285
posttranslational modification, 400
quantification, 126, 127
[³⁵S]GTPγS assay and, 2, 3, 5
specificity of, 398, 399
G proteins, α subunit, 190, 191, 354–356
in adenylyl cyclase regulation, 236
in affective disorders, 56
in alcoholism, 61
antidepressants and, 295–297
bacterial toxins and, 95
in bipolar disorders, 290, 291, 365, 366, 368
D1:D2 receptor interactions and, 95–98
in drug dependence, 60
fodrin and, 410, 411
lithium and, 64
lymphocytes and, 54
in major depression, 367
in mitral valve prolapse, 293
mutations in, 53, 54
neuroleptics and, 127, 128, 130–132
pituitary tumors and, 65
posttranslational modification, 402
in schizophrenia, 54, 55, 383, 384, 386–388, 409–412
specificity of, 398, 399
types, 398
G proteins, β subunit, 191, 356
in adenylyl cyclase regulation, 236
D1 D2 receptor interactions and, 98, 99
neuroleptics and, 127, 128, 130
posttranslational modification, 400
in schizophrenia, 387, 388
specificity of, 398, 399
G_i/G_o proteins, 3, 82, 386, 387, 388
G_i proteins, 55–57, 144
G_{olf} proteins, 155, 291
G_s proteins, in affective disorders, 55, 56, 57
GRK, *see* G protein receptor kinases

GTP
AA-[α-³²P] analog, 332, 337
in adenosine receptor radio-ligand studies, 335, 336
antidepressants and, 363
Gpp(NH)p analog, 208–211, 289, 290
G proteins and, 2, 3, 5, 191, 234, 235, 356, 394
melatonin receptors and, 228
GTPase
assay of G protein activity, 4, 5
in [³⁵S]GTPγS assay, 340–342
small-mol-wt G proteins and, 38, 39
GTPase-activating protein (GAP), 38–41, 245
GTP-binding proteins, *see* G proteins
Guanine nucleotides, activities of, 244
Guanosine diphosphate, *see* GDP
Guanosine triphosphate, *see* GTP
Guanylate cyclase, 250
Guanyl cyclase, 66

H

Hallucinations, 408
Haloperidol, 121, 122, 124–135, 403
Heart disease, 286
Heparin, 241
Heroin, self-administration paradigm, 194, 195
Hippocampus
antidepressants and, 295, 296
in schizophrenia, 382–386, 408
Homovanillic acid, 120
Hormone responsive elements (HREs), 68
Hormones, *see also* Melatonin; specific types
G proteins and, 260, 261
in mood and anxiety disorders, 307–310
“permissive,” 307
in signal transduction, 307–310
HPA, *see* Hypothalamic-pituitary-adrenal axis
HRE, *see* Hormone responsive elements

5-HT, lithium and, 357
5-HT receptors, 65, 66
5-HT_{1A} receptors, 256
 in antidepressant activity, 294, 296
 calcium mobilization and, 167, 168
 desensitization, 164, 168, 179
 G protein coupling specificity
 in, 166, 167
 inhibitory actions of, 164, 165
 lithium and, 64, 357
 in PLC stimulation, 165, 166
 prolactin and, 165
 uncoupling, 171–173, 177–179
5-HT₂ receptors
 lithium and, 357
 tricyclic antidepressants and, 361
Huntington's disease, 84, 122, 402
HVA, *see* Homovanillic acid
Hypothalamic-pituitary-adrenal axis (HPA), 309, 310
Hypothalamus, endocrine activity and, 255
Hypothyroidism, 309

I

IAP, *see* Islet-activating protein
¹²⁵I-APE, 334
IEGs, *see* Immediate early genes
iGluR, *see* Ionotropic glutamate receptors
i2 loop, phosphorylation, 178, 179
Imipramine, 296, 362
Immediate early genes (IEGs), 258
Immunoassay, in schizophrenia studies, 380–389, 409
Indoleamines, *see* Melatonin
Inositol phosphate
 in age-related disease, 58, 59
 opioid receptors and, 211
 in schizophrenia, 407
In situ hybridization,
 neurotransmitter receptors and, 1
Insomnia, 261, 262
2-Iodomelatonin, 245, 252
Ionotropic glutamate receptors (iGluRs), 67

IP₃, 58, 244, 396, 397
IP₃ receptors, 412
Ischemia, adenosine receptors and, 328–331, 342, 343
Islet-activating protein (IAP), 380–382
Isoelectric focusing, in analysis of small-mol-wt G proteins, 34–37
Isoprenylation, of small-mol-wt G proteins, 31, 32
Isoproterenol, 336, 362

J

Jet lag, 262
jun-B gene, 258

K

KFM 19, 343
Kindling, 310–312

L

Lateral temporal cortex, in schizophrenia, 382, 384, 385
LC, *see* Locus ceruleus
L-DOPA, 84, 87
 dyskinesia and, 153, 154
 Parkinson's disease and, 147
Leukocytes
 mononuclear, 288, 289, 290, 364–366, 368
 polymorphonuclear, 407
Lewis rat, 195
LH, *see* Luteinizing hormone
Light
 circadian rhythm and, 258
 gene expression and, 258
Limbic system, 60
 sensitization in, 311, 312
Lipids, 59, 68–70
Lipid vesicles, opioid receptor reconstitution and, 215, 216
Lithium, 55, 56, 131
 actions of, 63–65, 357
 adenylyl cyclase and, 299–302, 357–359
 ADP ribosylation and, 360, 361
 β-adrenergic receptors and, 302–304, 357–359

- bipolar disorder and, 299, 359
- competition with magnesium ion, 359, 360
- G proteins and, 299–304, 358–360, 402, 403
- melatonin receptors and, 261
- signal transduction pathways and, 355, 356
- Locus ceruleus (LC), 60
- Luteinizing hormone (LH), 239, 247, 248, 255, 256
- Luzindole, 253, 254
- Lymphocytes
 - in affective disorders, 56
 - G proteins and, 54, 407
 - lithium and, 301, 302
 - melatonin and, 248, 250
- M**
- Magnesium
 - competition with lithium, 359, 360
 - in [³⁵S]GTPγS assay, 9, 11
- Major depression (MDD), 353, 366–368
- Manic-depression, 56, 304
- MAP, *see* Microtubule-associated protein
- MAP kinase, 41
- McCune-Albright syndrome, 53, 284, 286, 401
- M-6 cells, melatonin binding sites in, 227
- MDD, *see* Major depression
- Medial temporal lobe, in schizophrenia, 388, 389
- Median eminence, 230
- MEL, *see* Melatonin
- Melanin, 240
- Melanoma, 227
- Melatonin
 - adenylyl cyclase and, 237–241
 - analogs, 245, 252
 - in calcium regulation, 247, 248, 255–257
 - cAMP and, 238–241, 248–250
 - cancer and, 225, 227
 - circadian rhythm and, 223, 224, 250–252
 - electrophysiology and, 252–254
 - endocrine function and, 254–257
 - gene expression and, 257–259
 - inhibition of gonadotropin-releasing hormone, 256
 - multiple signaling pathways, 248–250
 - neuropsychiatric disorders and, 259, 260
 - pharmacological actions, 225, 226
 - in PLC regulation, 245, 246
 - reproductive activity and, 224
 - sleep disorders and, 261, 262
 - transmembrane signaling, 237–248
- Melatonin receptors
 - antagonists, 253, 254
 - arterial, 227, 228
 - cloning, 231, 232
 - desensitization, 231
 - diurnal variations, 229, 230
 - downregulation, 228–231
 - G proteins and, 241, 242
 - high-affinity binding sites, 226–228
 - lithium and, 261
 - molecular structure, 232, 233
 - pharmacology, 232
 - in suprachiasmatic nuclei, 226–231
- Membranes
 - in age-related disease, 59
 - treatment of psychiatric disorders and, 68–70
- Mental disorders, *see* Neuropsychiatric disorders; specific types
- Mesenchyme, 165
- Mesolimbic dopamine system, 190–195
- Metabotropic glutamate receptors (mGluRs), 67
- Met-enkephalin, 146
- N-Methyl-D-aspartate (NMDA), 411
- mGluR, *see* Metabotropic glutamate receptors
- Mianserin, 362, 363
- Microtubule-associated protein (MAP), 62, 63
- Mitogen-activated protein (MAP) kinase, 41
- Mitral valve prolapse, 63, 292, 293

MNLs, *see* Mononuclear leukocytes
Monamines, 361
Monoamine oxidase inhibitors, 294–296
Mononuclear leukocytes (MNLs)
 in bipolar disorder, 290, 364–366
 in major depression, 366, 368
 in mood disorders, 288, 289
Mood disorders, *see also* Bipolar disorder; Major depression etiology, 283–287
 G proteins and, 289–291, 368, 369
 hormones and, 307–310
 mononuclear leukocytes and, 288, 289
 neurotransmitters and, 353
 second messengers and, 287–289
 signal transduction in, 312, 313
Mood stabilizers, 356–361, 369
Morphine, 21, 22, 403
 acute effects, 191
 in adenylyl cyclase regulation, 209–211
 cell tolerance to, 209
 chronic effects, 191–194
 downregulation of CREB, 196, 197
 mesolimbic dopamine system and, 190–195
Morphine receptors, 65
MPP, 152
MPTP, 87, 124
 lesion model, 151–153
Muscarinic receptors, 396
 in affective disorders, 55
 in age-related disease, 57, 58
 G protein coupling specificity in, 166, 167
 lithium and, 358, 359
Myristoylation, 387, 388, 400

N

NAC, *see* Nucleus accumbens
N-Acetylserotonin (NAS), 245, 246
N-Acetyltryptamine, 245
Naloxone, 6, 213
Naltrexone, 196, 197, 213

NAS, *see* N-Acetylserotonin
NECA, 340
NEM, *see* N-Ethylmaleimide
Nemonapride, labeled, 84, 85
N-Ethylmaleimide (NEM), 241
Neuroblastoma cells, in opiate receptor studies, 208–213
Neurofibromin, 38
Neuroleptics
 adenosine receptors and, 340–342
 dyskinesia and, 153, 154
 effects on brain, 125–135
 effects on dopamine receptors, 121–123, 129, 131
 extrapyramidal side effects, 123, 124, 128
 G proteins and, 124–135, 402, 403
 schizophrenia and, 119–121, 140
Neurons
 in behavioral sensitization, 311
 D1:D2 receptors in, 92, 94
 dopaminergic, 190
 in drug addiction, 59, 60, 190
 electrophysiology and, 252–254
 in opiate receptor studies, 208–213
 paragigantocellular, 60
 PKC-induced receptor uncoupling and, 180
Neuropsychiatric disorders, *see also* specific types
 adenosine receptors and, 342–344
 adenylyl cyclase in, 63
 dopamine receptors in, 86, 87
 G proteins and, 401, 402
 melatonin and, 259, 260
 treatment strategies, 68–70
Neurotensin, 146
Neurotransmitter receptors, *see also* specific types
 agonist efficacy and, 2
 catalytic activity, 19–21
 desensitization, 139
 dose response curve, 140–142
 G protein activation, 3, 4, 140–142
 localization, 4, 5
 radioligand binding assays, 1, 2, 4

- [³⁵S]GTPγS binding assay, 2, 3
- signal transduction and, 1–3
- in situ* hybridization and, 1
- striatal systems, 146, 147
- supersensitivity, 139
- in treatment of psychiatric disorders, 68–70
- Neurotransmitters
 - G proteins and, 354
 - small-mol-wt G proteins and, 42, 43
- NG108-15 cell line
 - G protein expression in, 211
 - in opiate receptor studies, 208–213
- NIH IMAGE, 12
- Nitrocellulose blot overlay assay, 32–34, 37, 38
- Nucleus accumbens (NAc), 60, 190, 403
 - chronic morphine effects in, 191–194
 - CREB downregulation in, 196–202
 - drug addiction and, 194, 195
 - G protein regulation in, 196–202
- O**
- 6-OHDA lesion model, 150, 151
- Oligonucleotides
 - antisense
 - CREB downregulation and, 197–202
 - in dopamine receptor studies, 96
 - in G protein “knockdown,” 155
 - mode of action, 197–199
 - phosphorothioate-modified, 198, 199
- Opiates, *see also* Morphine
 - acute effects, 191
 - cell tolerance to, 209
 - self-administration paradigm, 194, 195
- Opioid receptors
 - adenylyl cyclase and, 212
 - agonists, 21, 22
 - cloning, 214
 - coupling efficiency in, 20, 21
 - deglycosylation, 217, 218
 - discovery, 207
 - in drug dependence, 59, 60
 - G proteins and, 208, 211, 212
 - ligand precursors, 207
 - NG108-15 cell line studies, 208–213
 - purification, 213, 214
 - reconstitution into lipid vesicles, 215, 216
 - selective ligands for, 213
 - [³⁵S]GTPγS and, 6, 7, 10, 15
 - solubilization, 213, 214
 - Western blot analysis, 216–218
- ORL-1 peptide, 17
- P**
- Palmitoylation, 398
- Panic disorder, 63, 292, 293
- PAOPA, 125, 128, 131, 132, 133
- Paragigantocellular neurons, 60
- Parahippocampal gyrus, 382, 384, 385, 402
- Parkinson’s disease, 57–59
 - dopamine in, 140, 147, 148
 - dopamine receptors in, 87, 140
 - etiology, 147–149
 - MPTP lesion model, 151–153
 - 6-OHDA lesion model, 150, 151
- Pars tuberalis (PT), 224, 226, 230, 231
- Pathophysiology, G proteins and, 53, 54
- PC12 cells, 358, 360
- Peptidomimetics, 124
- “Permissive hormones,” 307
- Peroxisome proliferator activated receptor (PPAR), 70
- Pertussis toxin (PTX), ADP ribosylation
 - in affective disorders, 56
 - in age-related disease, 57
 - in behavioral sensitization, 311
 - G protein activation, 3, 95, 165, 193, 241, 355
 - heroin self-administration and, 194, 195
 - lithium and, 64, 300, 301, 302
 - in PLC regulation, 244, 245
 - in schizophrenia, 54, 55
 - valproic acid and, 307

- PET, *see* Positron emission tomography
- PGE1, *see* Prostaglandin E1 receptors
- pH, [³⁵S]GTPγS assay and, 16
- 2-Phenylmelatonin, 254
- Pheochromocytoma cells, 358, 360
- Phorbol esters, 163, *see also* TPA
- Phosphatidylinositol 4,5-bisphosphate, *see* PIP₂
- Phosphatidylserine, 163, 397
- Phosphodiesterase, 259
- Phosphoinositidase, *see* Phospholipase C
- Phosphoinositide (PI)
 - in bipolar disorders, 367
 - hormonal regulation of, 308
 - lithium and, 299, 300
- Phospholipase C (PLC), 163, 354
 - in adenylyl cyclase modulation, 239, 240
 - in age-related disease, 59
 - calcium mobilization and, 167, 168
 - dopamine-D2 receptors and, 165, 166
 - endocrine activity and, 256
 - opioid receptors and, 211
 - in receptor desensitization, 169, 170
 - regulation of, 242, 244–246, 308
 - in selective uncoupling, 177, 178
 - in signal transduction, 394, 395
- Phosphorylation
 - of i2 loop, 178, 179
 - in selective uncoupling, 177
- pI, small-mol-wt G proteins and, 37
- PIP₂, 242, 244, 396
- Pirenzepine, 359
- Pituitary gland, *see* Pars tuberalis
- Pituitary tumors, 65, 401
- PKA, *see* cAMP-dependent protein kinase A
- PKC, *see* Protein kinase C
- Platelets
 - in affective disorders, 56
 - G proteins in, 403–407
 - lithium and, 301, 302
- PLC, *see* Phospholipase C
- PLG, 124, 128, 132–135
- PMNL, *see* Polymorphonuclear leukocytes
- Polyacrylamide gel electrophoresis, *see* SDS-PAGE
- Polymorphonuclear leukocytes (PMNL), 407
- Positron emission tomography (PET), 84, 287
- Posttraumatic stress disorder (PTSD), 63, 293
- Potassium channels, 165, 247, 331
- PPAR, *see* Peroxisome proliferator activated receptor
- Prazosin, 245, 254
- Prefrontal cortex, 409
- Prenylation, 400
- Prodynorphin, 207
- Proenkephalin, 207
- Prolactin, 165
- Proopiomelanocortin, 207
- Propranolol, 336
- Prostaglandin E1 receptors (PGE1), 287, 403, 406, 407
- Protein, concentration in [³⁵S]GTPγS assay, 15
- Protein kinase A, *see* cAMP-dependent protein kinase A
- Protein kinase C (PKC), 55
 - in adenylyl cyclase modulation, 239, 240
 - calcium mobilization and, 171–173
 - dopamine-D2 receptor resistance to, 173–175
 - in electrical kindling, 311
 - functions, 163
 - hormonal regulation of, 308
 - lithium and, 304
 - negative feedback receptor inhibition, 163, 164
 - in Parkinson's disease, 57
 - pseudosubstrate domains, 175
 - in receptor desensitization, 168–170, 179
 - in schizophrenia, 407, 412
 - in signal transduction, 396, 397
 - site of receptor uncoupling, 170–173
 - subtypes, 397
- Pseudohypoparathyroidism (PsHP), 53, 284–286
- Pseudosubstrate domains, 173–176

PsHP, *see* Pseudohypoparathyroidism
Psychiatric disorders, *see*
Neuropsychiatric disorders
Psychotropic drugs, 59, 60
PTSD, *see* Posttraumatic stress
disorder
PTX, *see* Pertussis toxin
Putamen, in schizophrenia, 382–
386, 408

Q

Quinpirole, 88

R

rab3A protein, 42, 43
rab genes, 30, 31, 37, 42
Rabphilin, 43
rab protein, 31
Raclopride, labeled, 84–86, 88–90,
96, 98, 99
Radioligand binding
adenosine receptors and, 333–
336
D1:D2 receptor interactions
and, 88–90
neurotransmitter receptors and,
1, 2, 4
ral genes, 36, 37
ral protein, 31
rap genes, 37
Raphé neurons, 180
RAR, *see* Retinoic acid receptor
ras p21 protein, 30
farnesylation, 31
functions of, 40, 41
GTPase activity and, 38
Rats, strain differences in drug
addiction, 195, 196
Receptors, *see* G protein-coupled
receptors; Neurotransmitter
receptors; specific types
Refractory depression, 310
Regulators of G protein signaling
(RGS), 193, 194
Releasing hormone (RH), 239
Reproduction, melatonin and, 224
Reserpine, 151
Retinoic acid receptor (RAR), 70

R7G receptors, 257
RGS, *see* Regulators of G protein
signaling
RH, *see* Releasing hormone
RNA, antisense oligonucleotides
and, 197
Ro 15-1788, 342
R-PIA, 336, 340
Ryanodine receptor, 397, 412

S

Scatchard assay, 19, 412
SCH 23390, 88–90, 98, 99
Schizophrenia
adenylyl cyclase in, 54, 55, 402
 α subunit and, 54, 55, 383, 384,
386–388, 408–412
brain regions in, 379, 382–386,
408–412
cAMP-dependent protein
kinase A in, 412
cAMP in, 406, 407, 412
D1:D2 interactions, 87, 91, 94, 99
dopamine levels in, 120
dopamine receptors and, 54, 55,
65, 84–86, 120, 121, 387,
393, 402, 411, 413
dopaminergic hypothesis, 119, 120
G proteins and, 380–389, 403–
407, 413
hallucinations, 408
immunoassays and, 409
IP₃ receptors in, 412
neuroleptics and, 119–121, 140
striatal neurons and, 94
SCN, *see* Suprachiasmatic nuclei
SDS-PAGE, 381
in analysis of GTPase-activating
protein, 40
in analysis of small-mol-wt G
proteins, 34, 35
in nitrocellulose blot overlay
assay, 32, 33
in opioid receptor analysis, 214
SEC4 protein, 42
Seizures, adenosine receptors and,
342, 343
Sensitization
behavioral, 310–312
in drug addiction, 189

- Serotonin receptors, *see* 5-HT1A and 5-HT2 receptors
- [³⁵S]GTPγS
- in adenosine receptor studies, 337–342
 - electroconvulsive shock and, 298, 299
 - G protein binding and, 2, 3, 5
 - nitrocellulose blot overlay assay and, 33, 34
 - Scatchard assay and, 19
 - storage, 15
- [³⁵S]GTPγS assay
- advantages of, 16, 17
 - agonist concentration and, 16
 - agonist efficacy and, 20–22
 - anatomical applications, 23
 - coupling efficiency and, 18, 19–21
 - emulsion autoradiography and, 23
 - future directions, 22, 23
 - GDP concentrations in, 8, 9, 10, 14, 15
 - G protein activity and, 5
 - limitations of, 17–19
 - methodology, 11–16
 - pH and, 16
 - pharmacological specificity, 5–8
 - protein concentration and, 15
 - reduction of basal binding in, 8–11
- Signal transduction
- adenosine receptors and, 330–332
 - antidepressants and, 283, 284
 - behavioral sensitization and, 310–312
 - in bipolar disorder, 364, 365
 - G proteins and, 354, 355, 394–403
 - hormonal regulation of, 307–310
 - kindling and, 310–312
 - lithium and, 357, 358
 - in mood and anxiety disorders, 312, 313
 - neurotransmitter receptors and, 1–3
 - in striatum, 146, 147
 - in unipolar disorder, 363
- Sleep disorders, 261, 262
- Small-mol-wt G proteins
- antibody specificity and, 36, 37
 - in brain, 35–37
 - cancer and, 40, 41
 - classes, 30
 - exocytosis and, 42, 43
 - functions of, 40–43
 - genes for, 30, 31
 - GTPase-activating protein and, 38–40
 - homology to ras p21 protein, 30
 - isoelectric focusing and, 34–37
 - membrane binding and, 31, 32
 - neurotransmitter release and, 42, 43
 - nitrocellulose blot overlay assay, 32–34
 - pI values and, 37
 - posttranslational modification, 31, 32
 - regulation of effector molecules, 44
 - SDS-PAGE and, 32–35
- Sodium, in [³⁵S]GTPγS assay, 9, 338, 340
- Sodium fluoride, 402, 406
- Sodium valproate, 357, 360, 361, *see also* Valproic acid
- Somatostatin receptors, 166, 167, 398, 399
- Spiperone, labeled, 84, 85, 88
- Sprague-Dawley rat, 195
- SR 141716A, 6, 7
- Startle reflex, 87
- Steroids, in signal transduction, 308
- Striatal neurons, D1:D2 receptors in, 94
- Striatum
- dopamine-D1 receptor localization, 144–146
 - effects of neuroleptics on, 125–135
 - G proteins in, 143
 - output pathways, 146
 - in Parkinson's disease, 148, 149
 - signal transduction in, 146, 147
- Substance P, 146
- Substantia nigra pars compacta, 150

Substantia nigra pars reticulata, 146
Sulpiride, 132
Superior temporal cortex, 409, 410, 412
Suprachiasmatic nuclei (SCN)
 circadian rhythm and, 223, 224, 250–252
 electrophysiology in, 252–254
 endocrine activity and, 254, 255
 melatonin receptors in, 226–231
 regulation of gene expression in, 258, 259

T

T149, *see* Threonine 149
Tardive dyskinesia, 153, 154
Temporal cortex
 lateral, 382, 384, 385
 superior, 409, 410, 412
Temporal lobe
 medial, 388, 389
 in schizophrenia, 408–412
Thalamus, 146
 endocrine activity and, 254, 255
Thin-layer chromatography, in
 GTPase assay, 39, 40
Threonine 149 (T149),
 phosphorylation, 178, 179
Thrombin, 407
Thyroid hormone, in mood and
 anxiety disorders, 308–310
Thyroid tumors, 401
Thyrotropin receptors, 166, 241
Tolerance, in drug addiction, 189
Toxins, *see* Cholera toxin, Pertussis
 toxin
TPA, 163
 inhibition of calcium
 mobilization, 171–175
 in receptor desensitization, 171–173
 in selective uncoupling, 177
Transcription factors, *see* cAMP
 response element binding
 protein

Tricyclic antidepressants, 294, 296
1,4,5-trisphosphate, *see* IP₃
Tumors, 401
 endocrine, 53, 54, 284
 melatonin levels and, 225
 pituitary, 65

U

Unipolar disorder, 288, 289, 365

V

Valproic acid, 304–307, *see also*
 Sodium valproate
Vasoactive intestinal peptide
 (VIP), 248
Ventral tegmental area (VTA), 60,
 190
VIP, *see* Vasoactive intestinal
 peptide
VTA, *see* Ventral tegmental area

W

Western blots
 in G protein quantification, 126,
 127
 of opioid receptors, 216–218
WIN 55212-2, 6, 7
Withdrawal, in drug addiction,
 189

X

XAC, 334

Y

Yeast, small-mol-wt G proteins in,
 41, 42
ypt1 protein, 42

Z

Zimelidine, 362